Monday's Top Analyst Upgrades and Downgrades: Foot Locker, Halozyme Therapeutics, Kimberly-Clark, Occidental Petroleum, Texas Roadhouse, Trip.com and more

Investing

Published: May 17, 2021 8:50 am

Last Updated: August 10, 2021 2:32 pm

The futures traded lower on Monday as investors return after a furious end of the week rally that saw all of the major indexes close higher along with the transportation index. The across-the-board strength and the continued talking down of the inflation scenario helped to feed the buying, as investors risk appetite returned. Note though that despite the strong two-day rally, all the indexes ended lower for the week. With most first-quarter earnings reports released, investors are starting to factor in the potential for a sideways trading market for the summer as volume slows while travel returns.

Despite the concerns across Wall Street for tapering of the quantitative easing program and clear building inflationary pressures, the Federal Reserve is vowing to keep interest rates contained, which could be one reason for the continued moves higher in the equity markets, even after sell-offs. Note that money markets continue to see massive inflows, which is another big plus.

With major Wall Street firms still warning of the potential for impending 5% to 10% correction across the board, it makes sense for investors to continue building some cash reserves into the market strength while repositioning portfolios for the balance of the second quarter and the rest of 2021.

24/7 Wall St. reviews dozens of analyst research reports each day of the week with a goal of finding new ideas for investors and traders alike. Some of these daily analyst calls cover stocks to buy. Other calls cover stocks to sell or avoid. Remember that no single analyst call should ever be used as a basis to buy or sell a stock. Consensus analyst target data is from Refinitiv.

These are the top analyst upgrades, downgrades and initiations seen on Monday, May 17, 2021.

Aligos Therapeutics Inc. (NASDAQ: ALGS): Piper Sandler resumed coverage of the stock with an Overweight rating and a $47 price target. The consensus target is much lower at $35, and the stock closed Friday at $21.19, which was down almost 7% for the day.

ALSO READ: Colonial Pipeline Hack Moves Cybersecurity to the Spotlight: 4 Stocks to Buy Now

American Assets Trust Inc. (NYSE: AAT): KeyBanc Capital Markets raised Sector Weight rating to Overweight and has a $42 price target. The consensus target is lower at $32.13. The stock was last seen Friday trading at $34.97 a share.
BRF S.A. (NYSE: BRFS): Barclays downgraded it to Underweight from Equal Weight. The stock has traded in a 52-week range of $2.85 to $4.84 and has a $5.36 consensus price target. The shares closed Friday at $3.99.

Decker’s Outdoors Corp. (NASDAQ: DECK): Telsey Advisory raised the price target on the shares to $375 from $355, after the company posted impressive fiscal third-quarter results. The consensus price objective is up at $390.75, and Friday’s final trade was reported at $335.75, after almost a 4% gain for the day.

DoubleVerify Holdings Inc. (NYSE: DV): This company had a recent initial public offering, and Goldman Sachs started coverage with a Buy rating and a $47 price target. JPMorgan has an Outperform rating with a $40 target. Needham checks in with a Buy rating and a $41 price objective, and Canaccord Genuity’s Buy rating comes with a $40 target. The stock closed trading on Friday at $30.86.

Foot Locker Inc. (NYSE: FL): Telsey Advisory raised its $56 price target on the popular shoe retailer to $60. The consensus target is $59.17, but the stock closed above both levels at $64.60 on Friday.

Halozyme Therapeutics Inc. (NASDAQ: HALO): SVB Leerink started coverage at Outperform with a $56 price target. That compares with the lower consensus target of $49.40 and Friday’s closing print of $43.03.

Kimberly-Clark Corp. (NYSE: KMB): Zacks selected this as its Bear of the Day, suggesting that the pandemic boost looks to be over for this consumer staples giant. Shares last closed at $ 134.18, and the consensus price target is $141.81.